Pharmacoeconomic evaluation of antidepressant therapies

Manag Care. 2004 Jun;13(6 Suppl Depression):34-41.

Abstract

With today's emphasis in the managed care environment on evidentiary literature, new antidepressants must provide economic evidence of their value compared with previously available agents. Various pharmacoeconomic models have shown newer antidepressant agents to be cost-effective relative to older agents. The authors review methodologies and published results.

Publication types

  • Review

MeSH terms

  • Antidepressive Agents* / economics
  • Antidepressive Agents* / therapeutic use
  • Cost-Benefit Analysis*
  • Decision Support Techniques
  • Drug Costs
  • Economics, Pharmaceutical*
  • Managed Care Programs
  • Quality of Life
  • Randomized Controlled Trials as Topic
  • Serotonin Uptake Inhibitors / economics
  • Serotonin Uptake Inhibitors / therapeutic use
  • Treatment Outcome
  • United States

Substances

  • Antidepressive Agents
  • Serotonin Uptake Inhibitors